Automating Dermatology Specialty Drug Prior Auth for Biologics

Klivira streamlines **dermatology specialty drug prior auth** for high-cost biologics and advanced therapies, minimizing administrative burden and accelerating patient access to critical treatments.

Dermatology practices face significant challenges managing prior authorizations for specialty drugs, particularly biologics for chronic conditions like psoriasis and atopic dermatitis. The intricate web of payer policies, step therapy requirements, and medical vs. pharmacy benefit distinctions often leads to delays and denials. Klivira provides a robust solution to navigate these complexities efficiently.

The Distinct Landscape of Dermatology Specialty Drug Prior Auth

Dermatology practices frequently encounter prior authorization requirements for high-cost specialty drugs, including biologics for conditions such as psoriasis, psoriatic arthritis, atopic dermatitis, and hidradenitis suppurativa. These often involve complex step-therapy protocols and periodic re-authorizations, distinct from general medical PAs. Klivira's platform is engineered to address these unique demands.

Key PA Triggers in Dermatology

Biologics for Psoriasis & Psoriatic Arthritis (e.g., adalimumab, secukinumab, guselkumab, risankizumab)
Biologics for Atopic Dermatitis (e.g., dupilumab, tralokinumab, lebrikizumab)
Biologics for Hidradenitis Suppurativa
Advanced Skin Cancer Immunotherapies and Targeted Therapies
Select Mohs Micrographic Surgery stages and Phototherapy (home-based)

Navigating Medical vs. Pharmacy Benefit for Dermatology Biologics

Specialty drugs in dermatology often fall under either the medical or pharmacy benefit, a critical distinction influencing the PA submission channel. Klivira's platform automates this benefit-side determination per drug and payer, ensuring submissions are routed correctly. This includes leveraging NCPDP SCRIPT ePA for pharmacy-benefit drugs and integrating with provider portals, X12 278, or Da Vinci PAS for medical-benefit therapies.

Essential Documentation for Dermatology Specialty Drug PAs

Disease severity scores (PASI, BSA for psoriasis; EASI, SCORAD for atopic dermatitis)
Documentation of prior topical, phototherapy, or conventional systemic therapy trials
Pre-biologic screenings for TB and hepatitis
Age-specific indications for biologics (e.g., dupilumab)
Conformance with AAD Appropriate Use Criteria for Mohs surgery

Klivira's Automated Workflow for Dermatology PA Challenges

Klivira's platform is purpose-built to address the specific workflow constraints of dermatology. We integrate AAD-guideline-aware step-therapy logic for biologics, validate Mohs surgery against Appropriate Use Criteria, and manage periodic re-authorization cycles for chronic treatments. Our system automates the capture of necessary clinical data from EMRs, streamlining the documentation process and reducing common denial reasons.

Reducing Common Denial Reasons in Dermatology

Common denial reasons in dermatology, such as insufficient documentation of step therapy for psoriasis biologics or a mismatch with Mohs Appropriate Use Criteria, are directly addressed by Klivira's automation. Our intelligent workflows ensure all required clinical criteria, including disease severity scores and pre-biologic screenings, are captured and submitted accurately, improving first-pass approval rates.

Frequently asked questions

How does Klivira handle the medical vs. pharmacy benefit split for dermatology biologics?

Klivira automates the benefit-side determination for each specialty drug based on payer and patient context. It then routes pharmacy-benefit drugs via ePA channels like NCPDP SCRIPT and medical-benefit drugs through appropriate medical PA channels (X12 278, Da Vinci PAS, payer portals).

Can Klivira help with re-authorizations for chronic dermatology conditions?

Yes, Klivira supports the management of periodic re-authorizations common for chronic biologic treatments in dermatology. The platform tracks re-authorization cycles and assists in compiling updated clinical documentation to ensure continuous patient access.

How does Klivira ensure compliance with dermatology-specific guidelines like AAD or Mohs AUC?

Klivira's platform incorporates logic aligned with AAD Clinical Guidelines for step therapy and Mohs Appropriate Use Criteria. This ensures that submitted documentation reflects adherence to clinical best practices, reducing denials related to guideline non-conformance.

What specific documentation does Klivira automate for dermatology prior authorizations?

Klivira automates the extraction and population of critical documentation, including disease severity scores (PASI, EASI, BSA), prior therapy trials (topical, phototherapy, systemic), and pre-biologic screening results. This data is pulled from the EMR to fulfill payer requirements.

Does Klivira integrate with specialty pharmacies for fulfillment?

For pharmacy-benefit specialty drugs, Klivira coordinates the post-approval specialty-pharmacy fulfillment workflow. While Klivira doesn't directly manage program enrollment, it streamlines the handoff process to major specialty pharmacy partners.